On the other hand, the combined expression of GLS2-centered-signature-gene set was significantly regulated with poor prognosis in lung and leukemia while there was no significant relationship of clinical outcomes in colon and head & neck cancers (see Figure 7d(i–iv)), suggesting that interacting partners of GLS and GLS2 together regulate the clinical outcomes in cancers. This evidence concerns the gene GLS2 and leukemia.